NYU/Exiqon Team Finds New Blood-Based miRNA Markers for Melanoma Recurrence
June 16, 2011
NYU/Exiqon Team Finds New Blood-Based miRNA Markers for Melanoma Recurrence
Exiqon, which provided the array platform used for the miRNA discoveries, plans to work with the NYU team to validate the results with the eventual goal of creating a clinical prognostic test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- QuantiBact Shows How TINA-Modified Primers Increase PCR Efficiency, Robustness
June 21, 2012 / PCR Insider - Danish Team Developing miRNA Signatures to Diagnose Skin Diseases
March 22, 2012 / Gene Silencing News - DermTech Replicates Melanoma Test's Microarray Results on OpenArray Tech, Plans Further Validation
November 17, 2011 / PCR Insider - Exiqon Certifies Denmark's Aros to Provide miRNA PCR Services
September 8, 2011 / PCR Insider - Revising Molecular Dx Roadmap, Qiagen Will Migrate PCR Tests Across Automated Platforms
May 12, 2011 / PCR Insider